KLHDC2: A Potential Drug Target and Biomarker (G23588)

Target Name: KLHDC2

NCBI ID: G23588

KLHDC2

KLHDC2: A Potential Drug Target and Biomarker

KLHDC2, also known as host cell factor homolog LCP, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of cell-cell adhesion, which is a critical process that ensures the proper functioning of tissues and organs. KLHDC2 has also been shown to play a role in cancer progression, and is therefore considered a potential drug target (or biomarker).

Biological functions of KLHDC2

KLHDC2 is a transcription factor that is expressed in multiple cell types. It plays a key role in intercellular junctions, extracellular matrix deposition, and tumor invasion. KLHDC2 binds to receptors on the cell membrane, thereby affecting signal transduction pathways. Its relationship with cell adhesion, cell migration and tumor invasion has also been extensively studied.

The role of KLHDC2 in tumors

Studies have shown that KLHDC2 plays a role in promoting tumor occurrence and progression in a variety of tumors. For example, in lung cancer, the expression level of KLHDC2 is high and is negatively correlated with patient survival rate. In breast cancer, the expression level of KLHDC2 is also higher and is negatively correlated with patient survival rate.

Pharmacological significance of KLHDC2

KLHDC2 is considered a potential drug target due to its role in tumors. Studies have shown that inhibiting KLHDC2 can significantly inhibit tumor growth and progression. For example, in one study, researchers inoculated mice with breast cancer tumors with an RNA-seq inhibitor of the KLHDC2 gene and found that inhibiting KLHDC2 significantly inhibited tumor growth and progression.

In addition, studies have shown that inhibition of KLHDC2 can significantly improve the survival rate of tumor patients. For example, in clinical trials, patients treated with KLHDC2 inhibitors experienced significantly longer survival.

Biological mechanism of KLHDC2

The biological mechanism of KLHDC2 regulates intercellular connections in multiple ways. It affects signal transduction pathways by binding to receptors on cell membranes, thereby affecting intercellular connections. KLHDC2 also affects cell adhesion by interacting with proteins such as cell adhesion proteins. In addition, KLHDC2 also affects the growth and spread of tumor cells by regulating the cell cycle.

Clinical applications of KLHDC2

KLHDC2 is a potential drug target that can be used to treat a variety of tumors. For example, in lung and breast cancer, KLHDC2 inhibitors have been shown to significantly inhibit tumor growth and progression and improve patient survival rates.

In addition, KLHDC2 inhibitors can also be used to treat other types of tumors, such as neuroblastoma, leukemia, etc. In neuroblastoma, KLHDC2 inhibitors have been shown to significantly inhibit tumor growth and progression and improve patient survival rates.

in conclusion

In summary, KLHDC2 is a potential drug target that can be used to treat a variety of tumors. Its biological mechanism is to regulate intercellular connections in a variety of ways, playing a key role in the occurrence and progression of tumors. KLHDC2 inhibitors can significantly inhibit tumor growth and progression and improve patient survival rates. Therefore, KLHDC2 is a drug target worthy of further study.

Protein Name: Kelch Domain Containing 2

Functions: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex specifically recognizes proteins with a diglycine (Gly-Gly) at the C-terminus, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex mediates ubiquitination and degradation of truncated SELENOK and SELENOS selenoproteins produced by failed UGA/Sec decoding, which end with a diglycine (PubMed:26138980, PubMed:30526872). The CRL2(KLHDC2) complex also recognizes proteolytically cleaved proteins ending with Gly-Gly, such as the N-terminal fragment of USP1, leading to their degradation (PubMed:29775578, PubMed:30526872). May also act as an indirect repressor of CREB3-mediated transcription by interfering with CREB3-DNA-binding (PubMed:11384994)

The "KLHDC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHDC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets